Erschienen in:
03.07.2023 | Cardio-Oncology (LA Baldassarre, Section Editor)
An Increased Understanding of the Association Between Atherosclerosis and Immune Checkpoint Inhibitors
verfasst von:
Judah M. Ellison, Anju Nohria
Erschienen in:
Current Cardiology Reports
|
Ausgabe 8/2023
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Immune checkpoint inhibitor (ICI) therapy activates the host immune system to promote tumor cell death. This activation of the immune system can lead to off-target immune-related adverse events (irAEs). There is an established link between inflammation and atherosclerosis. The purpose of this manuscript is to review the existing body of literature discussing the potential association between ICI treatment and atherosclerosis.
Recent Findings
Pre-clinical studies suggest that ICI therapy may lead to T-cell-mediated progression of atherosclerosis. Recent retrospective clinical studies have shown higher rates of myocardial infarction and stroke with ICI therapy, particularly in patients with pre-existing cardiovascular risk factors. Additionally, small observational cohort studies have used imaging modalities to demonstrate higher rates of atherosclerotic progression with ICI treatment.
Summary
Early pre-clinical and clinical evidence suggests an association between ICI treatment and the progression of atherosclerosis. However, these findings are preliminary, and adequately powered prospective studies are needed to demonstrate a conclusive association. As ICI therapy is increasingly used to treat a variety of solid tumors, it is important to evaluate and mitigate the potential adverse atherosclerotic effects of ICI treatment.